$COHN

Cohen & Company Sets Release Date for Third Quarter 2025 Financial Results - Cohen & Co (AMEX:COHN)

PHILADELPHIA and NEW YORK, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Cohen & Company Inc. ( NYSE:COHN ) will release its financial results for the third quarter 2025 on Tuesday, November 4, 2025. The Company will host a conference call at 10:00 a.m. Eastern Time ( ET ) that day to discuss these results.

Original reporting
Benzinga · Globe Newswire
Published Oct 31, 2025, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2025, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$COHN
Neutral
medium confidence
Mentioned
$COHN
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$COHNNeutralMed
01

Why it matters

Earnings results can significantly influence the stock's short-term trend, especially if they deviate from analyst consensus.

02

Market read

High relevance for traders and investors focusing on financial sector earnings and short-term trading strategies.

03

What to watch

Market-wide macroeconomic conditions or sector-specific news could overshadow company-specific earnings impacts.

Relevance 6/10Timing: High, as the earnings release is scheduled for November 4, 2025.

Background

Cohen & Company Inc. is a financial services firm with upcoming quarterly earnings, which are closely watched by investors and analysts.

Company-level read

Ticker impact

$COHNNeutralMedium confidence
Context

High relevance due to upcoming earnings release.

Expected impact

Potential short-term increase or decrease depending on earnings results; expected to be a catalyst for volatility.

Evidence & confidence

Earnings releases typically cause short-term price swings; however, without prior earnings data or consensus estimates, the direction remains uncertain.

Market effects

The release may impact the financial services sector, especially if results differ significantly from expectations.

Potential influence on regional markets, particularly in the U.S. financial sector.

Limited, unless the company has significant international exposure or the results indicate broader economic trends.

Counterpoint

The earnings release may be a non-event if results align with expectations, leading to minimal price movement.

Key entities

  • Cohen & Company Inc.

    A financial services firm scheduled to release Q3 2025 results.

Related articles

$COHNMed

COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Cohen & Co Inc. (COHN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Mi

$COHNMedAI 8/10

2026 - 06 - 26 | Elroy Air to Become Publicly Traded Company via Business Combination with Inflection Point - led SPAC | NDAQ: CMII

Elroy Air will become a publicly traded company through a business combination with SPAC Columbus Circle Capital Corp II (Nasdaq: CMII), led by Inflection Point Asset Management. The deal values Elroy Air at about $800M pre-money and ~$1.0B enterprise value, with $165M+ committed PIPE capital. Closing is expected in Q4 2026. Elroy’s Chaparral VTOL drone targets 500+ lbs cargo; demand pipeline exceeds 1,400 aircraft and $5B potential revenue.

$BMYMed

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.